[心得] 韓國

看板BaseballXXXX作者ensuey (*^-^*)時間4年前 (2021/08/06 17:55)推噓2(2推 0噓 0→)

留言2則, 2人參與討論串2/4 (看更多)

South Korea’s COVID-19 vaccine candidates can be evaluated through comparison with previously authorized vaccines. This means domestic vaccine developers will no longer have to recruit large control groups for a phase 3 clinical trial. According to the Ministry of Food and Drug Safety on Wednesday, the government has revised guidelines for phase 3 clinical trials in a bid to accelerate the development of homegrown vaccines against COVID-19. Under the new rules, drugmakers would need just 4,000 volunteers to conduct a phase 3 clinical study of a vaccine candidate. Based on the findings, they can compare the immunogenicity of an already authorized vaccine with one under development to prove its efficacy. Cross-platform comparisons between already authorized vaccines and a candidate of a different type are also allowed. Several South Korean firms are developing vaccines now, including Genexine, which is developing a DNA vaccine against the novel coronavirus. There are currently no DNA-based COVID-19 vaccines anywhere, meaning that Genexine has no authorized DNA vaccine that the company can compare with its vaccine candidate. http://www.koreaherald.com/view.php?ud=20210630001048 韓國為了加速國產疫苗的進程 FDA已核准免疫橋接取代傳統三期而且不限於同種疫苗間的比較所以韓產的DNA疫苗亦可和現有疫苗比較再次打臉一堆以為只有自己說的是科學的偽科學仔 ~ -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 36.229.242.97 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/BaseballXXXX/M.1628243755.A.D0B.html 陳培哲: 這些研究數據在科學上一點價值都沒有，因為抗體效價不等於實際打疫苗的保護力，這是沒有用的數字，他連看都不想看院士 ? 打著科學名號反科學我呸 ~

推

Fitzwilliam

08/06 18:11, 4年前 , 1^F

08/06 18:11, 1^F

不過是個踐踏自己專業為政治服務的角色罷了 ~

推

CTBA

08/06 18:27, 4年前 , 2^F

08/06 18:27, 2^F

其實不止日韓法國也有支疫苗在做免疫橋接了現在國際上有疫苗廠牌的國家只有英美德中俄對還未有國產疫苗的國家來說免疫橋接絕對是未來趨勢因為疫苗就是戰略物資加速扶持國產避免受制他國本來就是正確的 ※ 編輯: ensuey (36.229.242.97 臺灣), 08/06/2021 18:42:35